Acute stress suppresses pain by activating brain pathways that engage opioid or non-opioid mechanisms. Here we show that an opioid-independent form of this phenomenon, termed stressinduced analgesia 1 , is mediated by the release of endogenous marijuana-like (cannabinoid) compounds in the brain. Blockade of cannabinoid CB 1 receptors in the periaqueductal grey matter of the midbrain prevents non-opioid stress-induced analgesia. In this region, stress elicits the rapid formation of two endogenous cannabinoids, the lipids 2-arachidonoylglycerol 2 (2-AG) and anandamide 3 . A newly developed inhibitor of the 2-AG-deactivating enzyme, monoacylglycerol lipase 4,5 , selectively increases 2-AG concentrations and, when injected into the periaqueductal grey matter, enhances stress-induced analgesia in a CB 1 -dependent manner. Inhibitors of the anandamide-deactivating enzyme fatty-acid amide hydrolase 6 , which selectively elevate anandamide concentrations, exert similar effects. Our results indicate that the coordinated release of 2-AG and anandamide in the periaqueductal grey matter might mediate opioid-independent stress-induced analgesia. These studies also identify monoacylglycerol lipase as a previously unrecognized therapeutic target.Stress activates neural systems that inhibit pain sensation. This adaptive response, referred to as stress-induced analgesia (SIA), depends on the recruitment of brain pathways that project from the amygdala to the midbrain periaqueductal grey matter (PAG) and descend to the brainstem rostroventromedial medulla and dorsal horn of the spinal cord 7 . Endogenous opioid peptides have key functions in this process 1,8 , but other as yet unidentified neurotransmitters are also known to be involved 1 . We proposed that endocannabinoids might be implicated in stress analgesia for two reasons. First, agonists of CB 1 receptors-the predominant cannabinoid receptor subtype present in the brain 9,10 -exert profound antinociceptive effects 7 and suppress activity in nociceptive neurons 11-14 . Second, CB 1 antagonists increase the activity of nociceptive rostroventromedial medulla neurons 14 and enhance sensitivity to noxious stimuli 15 , indicating that an intrinsic endocannabinoid tone might regulate descending antinociceptive pathways 7 . To study non-opioid SIA we delivered brief, continuous electric foot shock to rats and quantified their sensitivity to pain after stress by using the tail-flick test. As demonstrated previously 1,16 , this stimulation protocol caused a profound antinociceptive effect that was not affected by intraperitoneal (i.p.) injection of the opiate antagonist naltrexone (14 mg kg 21 ) (Fig. 1a). However, the response was almost abolished by administration of the CB 1 antagonist rimonabant (SR141617A, 5 mg kg

No abstract

Cannabinoids are antinociceptive in animal models of acute, tissue injury -, and nerve injury -induced nociception. This review examines the biology of endogenous cannabinoids (endocannabinoids) and behavioral, neurophysiological, and neuroanatomical evidence supporting the notion that cannabinoids play a role in pain modulation. Behavioral pharmacological approaches, in conjunction with the identifi cation and quantifi cation of endocannabinoids through the use of liquid and gas chromatography mass spectrometry, have provided insight into the functional roles of en docannabinoids in pain modulation. Here we examine the distribution of cannabinoid receptors and endocannabinoid-hydrolyzing enzymes within pain modulatory circuits to gether with behavioral, neurochemical, and neurophysiological studies that suggest a role for endocannabinoid signaling in pain modulation. This review will provide a comprehensive evaluation of the roles of the endocannabinoids 2-arachidonoylglycerol and anandamide in stress-induced analgesia. These fi ndings provide a functional framework with which to understand the roles of endocannabinoids in nociceptive processing at the supraspinal level.K EYWORDS: 2-arachidonoylglycerol , anandamide , CB1 , fatty acid amide hydrolase , monoacylglycerol lipase , periaqueductal gray , rostral ventromedial medulla

No abstract

No abstract